Oncopeptides completes patient enrollment in phase 2 PORT study
STOCKHOLM, May 5, 2021 /PRNewswire/ — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the Company has completed patient enrollment in the phase 2 PORT…
Comments Off on Oncopeptides completes patient enrollment in phase 2 PORT study